This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
July 19, 2011/PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its xTAG Respiratory Viral Panel FAST (RVP FAST). This front line test has the potential to significantly change the way respiratory viral testing is performed and complements the company's existing respiratory portfolio.
Laboratories and healthcare providers are looking for ways to improve efficiency while managing increasingly complex disease states. The value of multiplexed testing for respiratory viruses is well established with Luminex as the market leader in providing comprehensive multiplexed testing for respiratory viruses. The addition of xTAG RVP FAST assay to Luminex's RVP growing product portfolio brings additional testing options to diagnostic laboratories looking for a front line assay targeting eight essential respiratory pathogens and delivering up to 96 patient results in a few hours.
"Providing faster results from a broad panel makes it easier for physicians to quickly identify appropriate treatment. Better patient outcomes have the potential to reduce hospitalizations and the associated burden on the healthcare system," said
Rodney Arcenas, Ph.D., Clinical Scientist, Molecular Microbiology and Immunology for Memorial Healthcare System in
Hollywood, Florida. "A streamlined and scalable assay that produces results in shorter time is important in effectively managing fluctuating patient volumes and seasonal spikes typically associated with respiratory viral illnesses."
xTAG RVP FAST panel includes:
Respiratory Syncytial Virus (RSV)
Non-specific influenza A
With minimal hands-on-time from laboratory staff, xTAG RVP FAST offers clinical and diagnostic laboratories the ability to rapidly provide actionable patient results to physicians. In addition to cost and time savings for the laboratory, earlier detection and differentiation between viral and bacterial infections facilitate appropriate physician treatment decisions, improving patient care and helping to reduce healthcare costs.